Literature DB >> 3154309

The role of prostaglandins in mediating the effects of angiotensin converting enzyme inhibitors and other antihypertensive drugs.

S L Swartz1.   

Abstract

This review considers the hypothesis that angiotensin converting enzyme (ACE) inhibitors and other antihypertensive drugs may reduce blood pressure by altering the balance of vasoconstrictor and vasodilator hormones. Most cases of essential hypertension are characterized by increased vascular resistance. Since vascular resistance can be viewed as a net balance of offsetting vasoconstrictor and vasodilator neurohumoral forces, and since angiotensin II and norepinephrine can stimulate the synthesis of vasodilator prostaglandins that can in turn counteract peripheral vasoconstriction, we measured changes in vasoconstrictor (angiotensin II) and vasodilator (PGE2) hormones after giving different antihypertensive drugs. We found that the sulfhydryl containing converting enzyme inhibitor captopril increased vasodilator prostaglandin production (PGE2-metabolite) both acutely and chronically. This increase in PGE2-metabolite was not seen with the non-sulfhydryl converting enzyme inhibitor, enalapril.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3154309     DOI: 10.1007/bf02125831

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  19 in total

1.  Effect of furosemide on urinary excretion of prostaglandin E in normal volunteers and patients with essential hypertension.

Authors:  K Abe; M Yasujima; S Chiba; N Irokawa; T Ito; K Yoshinaga; T Saito
Journal:  Prostaglandins       Date:  1977-09

2.  Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.

Authors:  V Durão; M M Prata; L M Gonçalves
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

3.  Effects of short-term beta blockade on blood pressure, plasma thromboxane B2, and plasma and urinary prostaglandins E2 and F2 alpha in normal subjects.

Authors:  R M Graham; W B Campbell; E K Jackson
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

4.  Influence of central alpha 1 inhibition in patients with essential hypertension.

Authors:  P Lijnen; J Staessen; R Fagard; A Amery
Journal:  Chest       Date:  1983-02       Impact factor: 9.410

5.  Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction.

Authors:  L J Rubin; J D Lazar
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

Review 6.  Prostaglandins, their intermediates and precursors: cardiovascular actions and regulatory roles in normal and abnormal circulatory systems.

Authors:  G J Dusting; S Moncada; J R Vane
Journal:  Prog Cardiovasc Dis       Date:  1979 May-Jun       Impact factor: 8.194

7.  Relationship of renal prostaglandins to three diuretics.

Authors:  L Favre; M B Vallotton
Journal:  Prostaglandins Leukot Med       Date:  1984-06

8.  Time-dependent changes in prostaglandin excretion in response to frusemide in man.

Authors:  B Scherer; P C Weber
Journal:  Clin Sci (Lond)       Date:  1979-01       Impact factor: 6.124

9.  Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man.

Authors:  S L Swartz; G H Williams; N K Hollenberg; L Levine; R G Dluhy; T J Moore
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

10.  Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.

Authors:  T J Moore; F R Crantz; N K Hollenberg; R J Koletsky; M S Leboff; S L Swartz; L Levine; S Podolsky; R G Dluhy; G H Williams
Journal:  Hypertension       Date:  1981 Mar-Apr       Impact factor: 10.190

View more
  1 in total

1.  Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits.

Authors:  J R Schuh; D J Blehm; G E Frierdich; E G McMahon; E H Blaine
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.